Download dermadis - BioVision

DERMADIS
One line pitch:
Dermadis is a late preclinical biotech company developing breakthrough drugs to treat
inflammatory skin disorders (both orphan and large market).
Market Analysis:
As main objective Dermadis intends to bring its lead compound DM107 to clinical validation
(Phase I/IIb; exit option one) in the high medical need, orphan indication Netherton syndrome and
then achieve market access with 50-70 million product peak sales. Licensing-out/collaborative
alliance with large biotech/pharma for the related large market indication atopic dermatitis (AD) will
run in parallel upon securing orphan disease POC data. AD and related diseases constitute a
developed, multi-billion Euro market. Additionally, Dermadis is in contact with dermato-cosmetics
and veterinary medicine companies as supplier of active ingredients.
Business Proposition:
Dermadis is a key player in a class of emerging drug targets called “Kallikreins”. The company is
developing a proprietary biological, DM107, targeting this new family of targets to treat
dermatology disorders by controlling specific biological, pathological pathways. DM107 and lead
compounds are derived from a proprietary in-house technology platform engineering natural,
human protease inhibitors with increased target activity and selectivity. The biomimetics nature of
Dermadis' compounds allows also access to the dermato-cosmetics market as active ingredients.
COMPANY PROFILE
• Website:
www.dermadis.com
• Activity: Biotech
• Contact:
KUNDIG Christoph
[email protected]
• Location:
Avenue Marie Curie 218
Archamps Technopole
74160
France
Competitive Advantage:
• Founded in: 01/03/2010
Good competitive position and differentiated potential: A first-in-class therapeutic biologic as drug
to treat (1) a rare disease with high medical need and (2) highly prevalent dermatological
conditions with similar pathologies. DM107 has obtained orphan drug status by EMA and FDA.
The rational based on strong science has sparked interest from multiple pharma companies after
positive POC. The lead product is at the end of preclinical stage with successful manufacturing
and no toxicity in primates; clinical program to be initiated. As biomimetics, similar compounds
are intended to be marketed as active ingredients in cosmetic conditions.
• Employees: 5
Investment Attractiveness:
Dermadis offers a proprietary, first-in class advanced biotherapy in an orphan indication without
current treatment option/competion. The drug proved pharmacologically active and safe in animal
models and the secured orphan drug designation gives access to cost-efficient development and
market access and extended market protection. Pharmas with interest in Netherton Syndrome,
multiple expanding indications into large markets and anticipated early revenues through
dermato-cosmetic collaborations award the project a highly interesting financial potential with
limited risk based on different exit options and early decisive milestones.
IP Situation:
Robust intellectual property condition (2 patents) with long duration of exclusivity (orphan
designation): (1) Patent of use: Use of serine protease inhibitors in the treatment of skin diseases,
WO/2009/093119A2. Assignees: Dermadis SAS and INSERM. Status: Granted (EP, JP) and
Pending (2) Product patent: Inhibitor proteins of a protease and use thereof, WO/2004/087912.
Assignee: University of Lausanne, Switzerland. Dermadis holds exclusive, world-wide license for
use in dermatology Status: Granted
• Management:
Kündig Christoph
Managing Director and CSO
Dupuy Patrick
Medical Director
Ferreira Sandra
Operations & Administration
Officer
• Financial information (€):
- Company stage:
late preclinical
- Capital raised to date:
4.8 M Euro
- Monthly burn rate:
- Capital seeking and date:
3.5 M Euro (exit option 1)
• Investors:
Private Investors, ready for
participation later investment
round, BPI
• Referred by: